These progresses have been reached through multidisciplinary and translational approaches and we have no doubt that the next coming years will reveal to be fruitful in developing new drugs that will target p38 to improve therapeutic efficacy in diseases such cancer and cardiovascular pathologies. This evidence concerns the gene MAPK1 and cancer.